Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 12/23/2018 |
Start Date: | August 7, 2007 |
End Date: | October 2024 |
Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation (PBI)
Partial breast irradiation (PBI) is becoming a new paradigm for breast cancer radiation.[1]
No type I or II evidence is currently available to demonstrate equivalence to standard whole
breast radiotherapy, and a prospective randomized trial jointly sponsored by NSABP and RTOG
(NSABP B-39 and RTOG 0413) is currently accruing patients, comparing whole breast
radiotherapy to PBI, either by brachytherapy or external beam techniques (EB). Until the
results of this or similar trials are available, PBI remains a research domain, and it should
be offered to patients only in the context of a clinical experimental protocol.
No type I or II evidence is currently available to demonstrate equivalence to standard whole
breast radiotherapy, and a prospective randomized trial jointly sponsored by NSABP and RTOG
(NSABP B-39 and RTOG 0413) is currently accruing patients, comparing whole breast
radiotherapy to PBI, either by brachytherapy or external beam techniques (EB). Until the
results of this or similar trials are available, PBI remains a research domain, and it should
be offered to patients only in the context of a clinical experimental protocol.
Despite the fact that less extensive experience than that of brachytherapy is available, PBI
delivery through an external-beam has many advantages. First of all, it is likely to be more
acceptable to the patient since it is non-invasive and it does not require a surgical
procedure or anesthesia. Moreover, since it is delivered after surgery, the pathological
analysis of the segmental mastectomy specimen is available to inform the selection of the
best candidates. In addition, EB-PBI is likely to become more widely reproducible, since it
does not rely on the experience and skills of the radiation oncologist performing the
brachytherapy implant. Besides, once the technique is established, it can be widely applied
at any facility provided with a linear accelerator, without the risk presented by some
brachytherapy approaches that can not be completed because of the unfavorable interplay of
patient's anatomy with the technical limitations of the applicator. Finally, in terms of
health care economics, an external beam approach spares the costs of an extra surgical
procedure and that of several days of hospitalization (in the case of LDR brachytherapy).
delivery through an external-beam has many advantages. First of all, it is likely to be more
acceptable to the patient since it is non-invasive and it does not require a surgical
procedure or anesthesia. Moreover, since it is delivered after surgery, the pathological
analysis of the segmental mastectomy specimen is available to inform the selection of the
best candidates. In addition, EB-PBI is likely to become more widely reproducible, since it
does not rely on the experience and skills of the radiation oncologist performing the
brachytherapy implant. Besides, once the technique is established, it can be widely applied
at any facility provided with a linear accelerator, without the risk presented by some
brachytherapy approaches that can not be completed because of the unfavorable interplay of
patient's anatomy with the technical limitations of the applicator. Finally, in terms of
health care economics, an external beam approach spares the costs of an extra surgical
procedure and that of several days of hospitalization (in the case of LDR brachytherapy).
Inclusion Criteria:
- Post-menopausal women defined as either:
1. at least 2 years without menstrual period or
2. patients older than 50 with serological evidence of post-menopausal status or
3. hysterectomized patients of any age with FSH confirmation of post-menopausal
status
- pT1 breast cancer, excised with negative margins
- pN0 or sentinel node negative or N0 clinically if the tumor is < 1 cm in size
Exclusion Criteria:
- Previous radiation therapy to the ipsilateral breast
- Presence of a proportion of DCIS in the core biopsy specimen which is compatible with
extensive intraductal component (EIC)
We found this trial at
1
site
Click here to add this to my saved trials